Apolipoprotein E Allelic Frequency Altered in Women with Early-onset Breast Cancer
Apolipoprotein E Allelic Frequency Altered in Women with Early-onset Breast Cancer
复制标题
DOI：
10.1177/117822341000400005
复制
发表时间：
2010-01
期刊：
影响因子：
--
通讯作者：
Tirtsa Porrata-Doria;J. Matta;Summer F Acevedo
中科院分区：
文献类型：
--
作者：
Tirtsa Porrata-Doria;J. Matta;Summer F Acevedo
在妇女中，最常见的癌症类型是乳腺癌，在美国，每8名妇女中就有1名受到影响;在波多黎各，每10万人中就有70人会患某种类型的乳腺癌。因此，更好地了解乳腺癌的潜在风险因素可能会导致早期检测工具的开发。载脂蛋白E（apoE）基因已被认为是世界上几个人群的危险因素。ApoE作为脂蛋白和胆固醇在整个身体中的转运机制发挥作用，在人体中存在3种主要亚型（apoE 2，apoE 3和apoE 4）。apoE 4是否是乳腺癌的危险因素仍然存在争议。以前的研究要么包括所有年龄段（20-80岁）的受试者，要么专注于晚发性（50岁后）乳腺癌;没有一项专门关注早发性（50岁及以下）乳腺癌。本研究的目的是检查（在波多黎各人群中）apoE 4在非乳腺癌与乳腺癌患者中发生的相对频率的差异，并检查早发与晚发患者中apoE 4的潜在差异。我们发现只有早发性乳腺癌幸存者的apoE 4频率增加（比值比2.15），这与结合或调整年龄以及apoE 4和肿瘤大小减小之间的关联的研究结果相似。ApoE也是化疗后长期认知效应的潜在风险因素，并影响对激素替代的反应。我们的数据支持这样的理论，即了解有患乳腺癌风险的妇女的apoE基因型可能是有益的，因为这些知识将有助于预测肿瘤大小和制定治疗方案。
Among women, the most prevalent type of cancer is breast cancer, affecting 1 out of every 8 women in the United States; in Puerto Rico, 70 out of every 100,000 will develop some type of breast cancer. Therefore, a better understanding of the potential risk factors for breast cancer could lead to the development of early detection tools. A gene that has been proposed as a risk factor in several populations around the world is Apolipoprotein E (apoE). ApoE functions as a mechanism of transport for lipoproteins and cholesterol throughout the body, with 3 main isoforms present in humans (apoE2, apoE3, and apoE4). Whether or not apoE4 is a risk factor for breast cancer remains controversial. Previous studies have either included test subjects of all ages (20–80) or have focused on late-onset (after age 50) breast cancer; none has concentrated specifically on early-onset (aged 50 and younger) breast cancer. The objectives of this study was to examine (in a Puerto Rican population) the differences in the relative frequency of occurrence of apoE4 in non-breast cancer versus breast cancer patients and to examine, as well, the potential differences of same in early- versus late-onset patients. We found an increased frequency of apoE4 (odds ratio 2.15) only in early-onset breast cancer survivors, which is similar to the findings of those studies that combined or adjusted for age as well as for an association between apoE4 and decreased tumor size. ApoE is also a potential risk factor for long-term cognitive effects after chemotherapy and affects response to hormone replacement. Our data supports the theory that knowing the apoE genotype of women who are at risk of developing breast cancer may be beneficial, as such knowledge would aid in the prediction of tumor size and the development of treatment regimens.